Harvard University Postdoctoral Research Fellow 2005-2010 Cell Biology/RNAi/ Oncology
University of Virginia Research Associate 2004-2005 Developmental Biology/ Ocular Diseases
University of Virginia Ph.D. 1998-2004 Developmental Biology/ Ocular Diseases
GIST, Korea M.S. 1996-1998 Molecular Biology
Sungkyunkwan University, Korea B.S. 1989-1996 Biology
LegoChem Biosciences Chief Business Development Officer VP 2015-present (Antibody-Drug-Conjugates Antibiotics, Anticoagulants
Bioneer Corporation Director, New Drug, R&D Center 2012-2015 (Oncology/ Pulmonary Fibrosis)
Bioneer Corporation Therapeutic RNA Dev. Team leader 2010-2012 (Oncology/Pulmonary Fibrosis)
Alnylam Pharmaceuticals External Research Fellow 2008-2010 (RNAi Therapeutics/Hypercholesterolemia)
Since earning his Ph.D. from University of Virginia, Dr. Jeiwook (Jei) Chae has conducted research both in academic and industry settings, gaining invaluable experience in many aspects of discovery research, animal models for human diseases, and preclinical therapeutic testing. He has extensive experience and expertise in animal disease models, especially mouse tumor and fibrosis models as well as cell culture-based assays for the target discovery/validation and drug efficacy evaluation.
His postdoctoral research at Harvard University was primarily focused on elucidating the mechanism underlying spreading RNAi signals between cells, especially related to cancer biology. His collaborative preclinical research with a leading RNAi therapeutics company, Alnylam, provided important insights for the clinical development of RNAi therapeutics. Subsequently, he joined Bioneer, where he served as Director of Research and conducted preclinical evaluations of a siRNA-based drug technology as well as research into RNAi pipelines involving multiple diseases.
As VP and Chief Business Development Officer at LegoChem Biosciences Dr. Chae currently leads
company’s scientific endeavors and has guided academic and industry collaborations, advancing clinical development of pipeline programs including antibiotics, anti-coagulants, and Antibody-Drug Conjugates (ADC)- based cancer drug. The primary mission of Dr. Jei Chae and his colleagues in LegoChem Biosciences is to develop a clinically applicable ADC drug using a novel site-specific ADC technology developed by the company.
Honors & Awards